A new study suggests that ubrogepant, sold as Ubrelvy, could help prevent migraines before they fully develop.
Typically used to treat migraines, ubrogepant was tested during the migraine prodrome, the early phase marked by symptoms like light sensitivity. The study found that taking ubrogepant during this early stage can reduce migraine pain and its impact on daily life. Participants who took the drug reported less disability and better functioning compared to those given a placebo.
The drug works by inhibiting CGRP, a protein involved in migraine development. Although self-reported and not universally effective, the findings are promising for improving migraine management.